30
Views
5
CrossRef citations to date
0
Altmetric
Perspective

The role of mTORC1 in acne pathogenesis and treatment

Pages 617-622 | Published online: 10 Jan 2014

References

  • Cordain L, Lindeberg S, Hurtado M et al. Acne vulgaris: a disease of Western civilization. Arch. Dermatol. 38(12), 1584–1590 (2002).
  • Collier CN, Harper J C, Cafardi JA et al. The prevalence of acne in adults 20 years and older. J. Am. Acad. Dermatol. 58(1), 56–59 (2008).
  • Bhate K, Williams HC. Epidemiology of acne vulgaris. Br. J. Dermatol. 168 (3), 474–485 (2012).
  • Melnik B. Dietary intervention in acne: Attenuation of increased mTORC1 signaling promoted by Western diet. Dermatoendocrinol. 4(1), 20–32 (2012).
  • Burris J, Rietkerk W, Woolf K. Acne: The role of medical nutrition therapy. J. Acad. Nutr. Diet. 113 (3), 416–430 (2013).
  • Smith RN, Mann NJ, Braue A et al. The effect of a high-protein, low glycemic-load diet versus a conventional, high glycemic-load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J. Am. Acad. Dermatol. 57(2), 247–256 (2007).
  • Kwon HH, Youn JY, Hong JS et al. The clinical and histological effect of low glycaemic load diet in the treatment of acne vulgaris in Korean patients: a randomized, controlled trial. Acta Derm. Venereol. 92(3), 241–246 (2012).
  • Di Landro A, Cazzaniga S, Parazzini F et al. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. J. Am. Acad. Dermatol. 67(6), 1129–1135 (2012).
  • Lindeberg S, Eliasson M, Lindahl B et al. Low serum insulin in traditional Pacific Islanders: the Kitava Study. Metabolism 48(10), 1216–1219 (1999).
  • Melnik BC, John SM, Plewig G. Acne: risk indicator for increased body mass index and insulin resistance. Acta Derm. Venereol. doi: 10.2340/00015555-1677 (2013) ( Epub ahead of print).
  • Kumari R, Thappa DM. Role of insulin resistance and diet in acne. Indian J. Dermatol. Venereol. Leprol. 79(3), 291–299 (2013).
  • Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J. Biol. Chem. 285(19), 14071–14077 (2010).
  • Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell. Biol. 12(1) 21–35 (2011).
  • Bakan I, Laplante M. Connecting mTORC1 signalling to SREBP-1 activation. Curr. Opin. Lipidol. 23(3), 226–234 (2012).
  • Yoon MS, Zhang C, Sun Y et al. Mechanistic target of rapamycin (mTOR) controls homeostasis of adipogenesis. J. Lipid Res. 54(8), 2166–2173 (2013).
  • Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J. Cell Sci. 126(8),1713–1719.
  • Dodd KM, Tee AR. Leucine and mTORC1: a complex relationship. Am. J. Physiol. Endocrinol. Metab. 302(11), E1329–E1342 (2012).
  • Melnik BC, John SM, Schmitz G. Milk is not just food but most likely a genetic transfection system activating mTORC1 signaling for postnatal growth. Nutr. J. 12, 103 (2013).
  • Morris C, O´Grada C, Ryan M et al. The relationship between BMI and metabolomics profiles: a focus on amino acids. Proceed. Nutr. Soc. 71(4), 634–638 (2012).
  • Melnik BC. Diet in acne: further evidence for the role of nutrient signalling in acne pathogenesis. Acta Derm. Venerol. 92(3), 228–231 (2012).
  • Melnik BC, Zouboulis CC. Potential role of FoxO1 and mTORC1 in the pathogenesis of Western-diet induced acne. Exp. Dermatol. 22(5), 311–315 (2013).
  • Hay N. Interplay between FOXO, TOR, and Akt. Biochim. Biophys. Acta 1813(11), 1965–1970 (2011).
  • Melnik BC, Schmitz G. Are therapeutic effects of antiacne agents mediated by activation of FoxO1 and inhibition of mTORC1? Exp. Dermatol. 22(7), 502–504 (2013).
  • Abali R, Yuksel MA, Aktas C et al. Decreased ovarian reserve in female Sprague-Dawley rats induced by isotretinoin (retinoic acid) exposure. Reprod. Biomed. Online. 27(2), 184–191 (2013).
  • Melnik BC. Isotretinoin and FoxO1: A scientific hypothesis. Dermatoendocrinol. 3(3), 141–165 (2011).
  • Fröjdö S, Cozzone D, Vidal H et al. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. 406(3), 511–518 (2007).
  • Melnik BC. Western diet-mediated mTORC1-signaling in acne, psoriasis, atopic dermatitis, and related diseases of civilization: Therapeutic role of plant-derived natural mTORC1 inhibitors. In: Bioactive Dietary Factors and Plant Extracts in Dermatology, Watson RR, Zibadi S ( Eds.). Springer New York Heidelberg Dordrecht London, chapter 37, 397–419, (2013).
  • Fabbrocini G, Staibano S, De Rosa G et al. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. Am. J. Clin. Dermatol. 12(2), 133–141 (2011).
  • Docherty JJ, McEwen HA, Sweet TJ et al. Resveratrol inhibition of Propionibacterium acnes. J. Antimicrob. Chemother. 59(6) 1182–1184 (2007).
  • Coenye T, Brackman G, Rigole P et al. Eradication of Propionibacterium acnes biofilms by plant extracts and putative identification of icariin, resveratrol and salidroside as active compounds. Phytomedicine 19(5), 409–412 (2012).
  • Huang CH, Tsai SJ, Wang YJ et al. EGCG inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Mol. Nutr. Food Res. 53(9), 1156–1165 (2009).
  • Elsaie ML, Abdelhamid MF, Elsaaiee LT, Emam HM. The efficacy of topical 2% green tea lotion in mild-to-moderate acne vulgaris. J. Drugs Dermatol. 8(4), 358–364 (2009).
  • Mahmood T, Akhtar N, Khan BA et al. Outcomes of 3% green tea emulsion on skin sebum production in male volunteers. Bosn. J. Basic. Med. Sci. 10(3), 260–264 (2010).
  • Im M, Kim SY, Sohn KC et al. Epigallocatechin-3-gallate suppresses IGF-I-induced lipogenesis and cytokine expression in SZ95 sebocytes. J. Invest. Dermatol. 132(12) 2700–2708 (2012).
  • Yoon JY, Kwon HH, Min SU et al. Epigallocatechin-3-gallate improves acne in humans by modulating intracellular targets and inhibiting P. acnes. J. Invest. Dermatol. 133(2), 429–440 (2013).
  • Zhou H, Luo Y, Huang S. Updates of mTOR inhibitors. Anticancer Agents Med. Chem. 10(7), 571–581 (2010).
  • Feldman ME, Shokat KM. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor kinase domain inhibitors (TORKinibs). Curr. Top. Microbiol. Immunol. 347, 241–262 (2010).
  • Liu Q, Kang SA, Thoreen CC et al. Development of ATP-competitive mTOR inhibitors. Methods Mol. Biol. 821, 447–460 (2012).
  • Danby FW. Turning acne on/off via mTORC1. Exp. Dermatol. 22(7), 505–506 (2013).
  • Silverberg NB. Whey protein precipitating moderate to severe acne flares in 5 teenaged athlethes. Cutis 90(2), 70–72 (2012).
  • Simonart T. Acne and whey protein supplementation among bodybuilders. Dermatology 225(3), 256–258 (2012).
  • Danby FW. Acne, dairy and cancer: the 5alpha-P link. Dermatoendocrinol. 1(1), 12–16 (2009).
  • Rubin MG, Kim K, Logan AC. Acne vulgaris, mental health and omega-3-fatty acids: a report of cases. Lipids Health Dis 7, 36 (2008).
  • Cordain L. The Dietary Cure for Acne. Paleo Diet Enterprises, CO, USA (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.